Cargando…

Thromboembolic Events in Patients with HER2-Negative, Hormone Receptor-Positive, Metastatic Breast Cancer Treated with Ribociclib Combined with Letrozole or Fulvestrant: A Real-World Data

PURPOSE: Cyclin dependent kinase (CDK) 4/6 inhibitors (palbociclib, ribociclib and abemaciclib) modulate endocrine resistance and are integral treatment for patients with advanced hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Since their appr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdel-Razeq, Hikmat, Sharaf, Baha’, AlMasri, Rama, Abdel-Razeq, Rashid, Tamimi, Faris, Khader, Omar, Salama, Osama, Abunasser, Mahmoud, Edaily, Sarah, Abdulelah, Hazem
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921668/ https://www.ncbi.nlm.nih.gov/pubmed/35300061 http://dx.doi.org/10.2147/CMAR.S353584

Ejemplares similares

Vitiligo-Like Lesions in a Patient with Metastatic Breast Cancer Treated with Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor: A Case Report and Literature Review
por: Sharaf, Baha', et al.
Publicado: (2022)

Urinary bladder metastasis from primary breast cancer, a rare and challenging diagnosis. A case report and literature review
por: Abdel-Razeq, Rashid, et al.
Publicado: (2022)

Rates of Variants of Uncertain Significance Among Patients With Breast Cancer Undergoing Genetic Testing: Regional Perspectives
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2022)

Patterns and Prevalence of BRCA1 and BRCA2 Germline Mutations Among Patients with Triple-Negative Breast Cancer: Regional Perspectives
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2021)

Differences in Treatment Outcomes Between Patients with HER2-Low versus HER2-Zero, Hormone Receptor-Positive Advanced-Stage Breast Cancer Treated with Ribociclib
por: Sharaf, Baha’, et al.
Publicado: (2023)

Tumor characteristics and treatment outcomes of older patients with breast cancer in Jordan
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2020)

Prevalence and predictors of germline BRCA1 and BRCA2 mutations among young patients with breast cancer in Jordan
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2021)

Late presentation and suboptimal treatment of breast cancer among Syrian refugees: a retrospective study
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2021)

Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant Setting
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2022)

Guideline-Based, Multi-Gene Panel Germline Genetic Testing for at-Risk Patients with Breast Cancer
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2023)

Management Strategies of Breast Cancer Patients with BRCA1 and BRCA2 Pathogenic Germline Variants
por: Edaily, Sarah, et al.
Publicado: (2022)

Predictors of Venous Thromboembolism in Patients With Testicular Germ Cell Tumors: A Retrospective Study
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2021)

Complete and Durable Response to Tamoxifen and Ovarian Ablation in the Treatment of Metastatic Breast Cancer
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2021)

Breast Cancer in Geriatric Patients: Current Landscape and Future Prospects
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2022)

Venous thromboembolism prophylaxis for hospitalized medical patients, current status and strategies to improve
por: Abdel-Razeq, Hikmat
Publicado: (2010)

The Saudi clinical practice guideline for the prophylaxis of venous thromboembolism in long-distance travelers
por: Abdel-Razeq, Hikmat
Publicado: (2017)

Delays in Initiating Anti-Cancer Therapy for Early-Stage Breast Cancer—How Slow Can We Go?
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2023)

Inferior vena cava filters in cancer patients: to filter or not to filter
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2011)

Dealing with thrombocytopenia during anticoagulation with heparins for active venous thromboembolism: a play-it-safe practical approach
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2011)

Clinicopathological Characteristics And Treatment Outcomes Of Breast Cancer Among Adolescents And Young Adults In A Developing Country
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2019)

Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look!
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2018)

Aggressiveness of Cancer Care at End of Life in Patients with Metastatic Breast Cancer in Jordan
por: Abunasser, Mahmoud, et al.
Publicado: (2023)

Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial
por: Cottu, Paul, et al.
Publicado: (2022)

Differences in clinicopathological characteristics, treatment, and survival outcomes between older and younger breast cancer patients
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2021)

The application of clinical variables and models to predict pulmonary embolism in cancer patients: a comprehensive single cancer center experience
por: Mansour, Asem, et al.
Publicado: (2013)

Comparative efficacy & safety of buparlisib plus fulvestrant, fulvestrant plus dalpiciclib, and ribociclib plus letrozole for postmenopausal, hormone receptor-positive, and HER2-negative breast cancer
por: Liu, Qi, et al.
Publicado: (2023)

Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
por: Abdel-Razeq, Hikmat
Publicado: (2016)

Gonadotropin-releasing hormone agonists during chemotherapy for ovarian function and fertility preservation for patients with early-stage breast cancer
por: Abdel-Razeq, Hikmat
Publicado: (2019)

Prognostic Significance of Serum Vitamin D Levels in Egyptian Females with Breast Cancer
por: Abdel-Razeq, Hikmat
Publicado: (2019)

Expanding the search for germline pathogenic variants for breast cancer. How far should we go and how high should we jump? The missed opportunity!
por: Abdel-Razeq, Hikmat
Publicado: (2021)

Surgical options for patients with early-stage breast cancer and pathogenic germline variants: an oncologist perspectives
por: Abdel-Razeq, Hikmat
Publicado: (2023)

Metaplastic Breast Carcinoma: Experience of a Tertiary Cancer Center in the Middle East
por: Erjan, Ayah, et al.
Publicado: (2021)

Patterns and predictors of thromboembolic events among patients with gastric cancer
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2020)

Thrombosis and Anticoagulant Therapy Among Pediatric Cancer Patients: Real-Life Data
por: Hashem, Hasan, et al.
Publicado: (2021)

The Application of the Lymphoma International Prognostic Index to Predict Venous Thromboembolic Events in Diffuse Large B-Cell Lymphoma Patients
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2021)

Prolonged Neutropenia and Yellowish Discoloration of the Skin, But Not the Sclera, Following Excessive Turmeric Raw Root Ingestion
por: Abdel-Razeq, Rashid, et al.
Publicado: (2021)

Current neoadjuvant treatment options for HER2-positive breast cancer
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2011)

Fondaparinux vs warfarin for the treatment of unsuspected pulmonary embolism in cancer patients
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2016)

Treatment options for patients with hormone receptor-positive, HER2-negative advanced-stage breast cancer: maintaining cyclin-dependent kinase 4/6 inhibitors beyond progression
por: Horani, Malek, et al.
Publicado: (2023)

Treatment of anemia in cancer patients undergoing chemotherapy with intravenous ferric carboxymaltose without erythropoiesis-stimulating agents
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6nsvkb96f5slb9ndkdtqdkdmm2